Premium
Design of clinical trials involving multiple hypothesis tests with a common control
Author(s) -
Schou I. Manjula,
Marschner Ian C.
Publication year - 2017
Publication title -
biometrical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 63
eISSN - 1521-4036
pISSN - 0323-3847
DOI - 10.1002/bimj.201500230
Subject(s) - heteroscedasticity , variance (accounting) , sensitivity (control systems) , mathematics , clinical trial , optimal design , sample size determination , mathematical optimization , sequential analysis , clinical study design , range (aeronautics) , computer science , statistics , medicine , materials science , accounting , pathology , electronic engineering , engineering , business , composite material
Randomized clinical trials comparing several treatments to a common control are often reported in the medical literature. For example, multiple experimental treatments may be compared with placebo, or in combination therapy trials, a combination therapy may be compared with each of its constituent monotherapies. Such trials are typically designed using a balanced approach in which equal numbers of individuals are randomized to each arm, however, this can result in an inefficient use of resources. We provide a unified framework and new theoretical results for optimal design of such single‐control multiple‐comparator studies. We consider variance optimal designs based on D ‐, A ‐, and E ‐optimality criteria, using a general model that allows for heteroscedasticity and a range of effect measures that include both continuous and binary outcomes. We demonstrate the sensitivity of these designs to the type of optimality criterion by showing that the optimal allocation ratios are systematically ordered according to the optimality criterion. Given this sensitivity to the optimality criterion, we argue that power optimality is a more suitable approach when designing clinical trials where testing is the objective. Weighted variance optimal designs are also discussed, which, like power optimal designs, allow the treatment difference to play a major role in determining allocation ratios. We illustrate our methods using two real clinical trial examples taken from the medical literature. Some recommendations on the use of optimal designs in single‐control multiple‐comparator trials are also provided.